Previously in New York state, OSI Pharmaceuticals - formerly known as Oncogene Science, Inc. (OSI) - has been extensively involved in SBIR from early in the program. In May 2010, the firm was acquired by Japanese pharmacuetical giant Astellas Pharma. With facilities in CO, NY and the UK, the firm's major focus is on development, manufacture, and marketing of high quality, ready-to-use cancer reagent systems to commercial and clinical research customers worldwide. To further establish the clinical utility of these tumor markers, the firm's core competencies include immunodiagnostics (ELISA) expertise and a significant worldwide patentestate (e.g., HER-2/neu, ras, p53 and Retinoblastoma).. Following various acquisitions and divestitures, in 1997 Oncogene Science, Inc. changed its name to OSI Pharmaceuticals, Inc. (OSIP), and evolved Oncogene Science Diagnostics (OSD) into a wholly owned subsidiary of OSIP. In late November 1999, OSIP sold OSD to the diagnostics business group of Bayer Corporation, headquartered in Leverkusen, Germany - one of the largest medical diagnostics companies in the world, is focused to become the world leader in cancer diagnostics. The company's FDA-approved Tarceva treats non-small cell lung cancer and pancreatic cancer and is in development for other indications as well. Partner Genentech co-promotes the drug in the US, and it is marketed internationally by Roche. OSI and marketing partner Pfizer also sell Macugen, a treatment for the "wet" form of age-related macular degeneration (AMD), a degenerative eye disease; it got the drug when it acquired Eyetech, later renamed (OSI) Eyetech, in 2005. The company's pipeline of drug candidates is focused on new anti-cancer compounds. Additionally, through UK subsidiary Prosidion, it is working on treatments for diabetes and obesity
